Trends

Dealmaking and R&D

Text search

Sort by Name

Click to order products descending

Display 15 Products per page

When Deals Go Wrong: Lessons from Failure

$2,995.00

Acquisitions and licensing are core to pharma and big biotech growth as pipelines thin and assets lose patent protection. Yet a look back at prior years’ eye-popping deal sums reveals many billions of dollars of write-offs and lost value. Key assets failed or disappointed in at least half of 2014’s largest acquisitions and licensing deals. Failure is part of the drug discovery landscape, but some lessons can be learned from dud deals.

July 12, 2019
Find out more
Trends in Gene Therapy

$2,995.00

Datamonitor Healthcare has carried out a comprehensive analysis of gene therapy products in commercial development worldwide based on information derived from Pharmaprojects.
October 14, 2016
Find out more
Regenerative Medicine Landscape

$2,995.00

The competitive landscape for regenerative medicine continues to evolve. As private sector investment in active players continues, efforts by governments in the US and EU are helping to advance the field, including the recent passage of the 21st Century Cures Act in the US, providing a special status pathway for regenerative medicine advanced therapies.
July 21, 2017
Find out more
R&D Trends 2016

$2,995.00

Over the nine-year period from 2006 to 2014, the Big Pharma, Mid Pharma, and Japan Pharma peer sets collectively spent an annual average of $94bn on R&D of pharmaceuticals, with spending growing at a compound annual growth rate (CAGR) of 6%.
October 17, 2016
Find out more
Profitability Assessment of Branded Generic Inhalers

$2,995.00

We set out to examine the extent to which order of market entry influences the prospects of achieving a satisfactory return on investment for companies developing branded generic and generic inhaled products.
October 31, 2016
Find out more
Product Launch and Commercialization Strategies

$2,995.00

Recent years have seen changes in the marketplace that have made successful new drug launches difficult to achieve. Many therapy areas are becoming hypercompetitive, with similar treatments jostling for position, and even those products with evidence of superior efficacy or better tolerability still have to overcome reimbursement hurdles.
December 12, 2016
Find out more
Precision Medicine and the Future of Healthcare

$2,995.00

Precision medicine is typically associated with the use of therapies that target particular disease-linked genetic mutations, identified via a diagnostic test.
October 14, 2016
Find out more
Post-ADPD Alzheimer’s Disease KOL Interview

$599.00

Key Highlights BIIB-037 Amyloid beta PET data show positive Abeta reduction; cognitive results are not interpretable with such small numbers. (BIIB) BIIB-037 Phase Ib result interpretation may be effected by the ApoE4 dropouts in the treatment arm. (BIIB) MK-8931 and BIIB-037 show sufficient target engagement, but there is no evidence to date that amyloid clearance […]
April 8, 2015
Find out more
Pharma’s Patient Centricity

$2,995.00

Patient centricity is the buzzword of this decade, and necessarily so: it either underpins, or is an inevitable result of, all the forces shaping today’s rapidly evolving healthcare landscape.
October 17, 2016
Find out more
Pharma-Payer Partnerships in Emerging Markets

$2,995.00

Payer partnerships are becoming widespread as emerging markets become wealthier, but access challenges remain. Partnerships with proven success include “strategic philanthropy,” patient access programs, tiered pricing, and service support models.
July 26, 2017
Find out more
Pharma Externalization Strategies 2016: Externalization is Critical to Pharma Revenue

$2,995.00

Pharmaceutical companies constantly re-assess their pipelines and portfolios to determine the best strategies for their business.
October 17, 2016
Find out more
PD-1/L1 Immunotherapies: Historical Sales and Market Trend Analysis Report

$7,500.00

Bristol-Myers Squibb’s (BMS) Opdivo (nivolumab) has outpaced Merck’s Keytruda (pembrolizumab) primarily
in non-small cell lung cancer (NSCLC) because of its early approval in squamous NSCLC, updated National
Comprehensive Cancer Network (NCCN) guidelines in 2015,
December 22, 2016
Find out more
New Pharma Models for a New Healthcare Era

$2,995.00

This analysis includes insights from eight interviewed experts from pharma, medical device, or digital health companies.
December 20, 2018
Find out more
Mid Pharma Outlook

$3,000.00

Total sales from the mid pharma peer set amounted to $69.4bn in 2011; by the end of 2012, this figure rose by 1.6% to $71.0bn. During 2012 the peer set constituents exhibited varying degrees of sales growth.
September 28, 2016
Find out more
Innovation in Deal-Making

$3,000.00

In order to continually and effectively compete with its peers, as well as with smaller specialty pharmaceutical companies and biotechnology companies, the top 20 global pharmaceutical peer set turns to deal-making as a means to balance out its internally developed portfolio, and to take advantage of the broader capabilities of partners or takeover targets.
June 13, 2018
Find out more

Sign up to the Pharma Intelligence Report Store Newsletter to get the latest blogs, news, reports and discounts!

Pharma Intelligence

This is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Call Back

Name

Email *

Company name *

Phone number *